M-J. Ahn - Sch Med, Sungkyunkwan Univ

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 59 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

152P Treatment (tx) patterns and clinical outcomes in unresectable stage III epidermal growth factor receptor-mutation positive (EGFRm) non-small cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT): Interim analysis of a global real-world (RW) study

J. Neal, J.B. Lee,M-J. Ahn, R. Ariyasu, C. Nash, D. Smith, S. Nagar, M. Jimenez, D.A. Kahangire, Y.J. Kim, F. Nasirova, S.H. Lin

ESMO Open (2024)

引用0浏览0引用

38P Real-world treatment patterns and effectiveness of subsequent treatments following first-line (1L) brigatinib for patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) from ALTA-1L

A. Delmonte,M-J. Ahn, S. Ghosh, M.J. Hochmair,T-Y. Yang,J.C-H. Yang,J-Y. Han, K.H. Holmskov,Y. Wu, Y. Wan, M. Lin, J. Kretz,

ESMO Open (2024)

引用0浏览0引用

59P Datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC): Nonsquamous (NSQ) histology in the phase III TROPION-Lung01 trial

N. Girard, I. Okamoto, A.E. Lisberg, E. Pons-Tostivint, R. Cornelissen, M.H. Hong, L. Paz-Ares,D. Vicente Baz, S. Sugawara,M. Cobo Dols, M. Pérol, C. Mascaux,

ESMO Open (2024)

引用0浏览0引用

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study

A. Psyrri, J. Fayette,K. Harrington, M. Gillison,M. -J. Ahn, S. Takahashi, J. Weiss,J. -P. Machiels, S. Baxi, A. Vasilyev, A. Karpenko, M. Dvorkin,

ANNALS OF ONCOLOGY（2023）

引用17浏览0WOS引用

Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study

H. A. Jung, S. Park,S. -H. Lee,J. S. Ahn,M. -J. Ahn,J. -M. Sun

ESMO OPENno. 6 (2023): 102068

引用0浏览0WOS引用

Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01

M-J. Ahn, A. E. Lisberg,L. Paz-Ares, R. Cornelissen,N. Girard, E. Pons-Tostivint,D. Vicente Baz,S. Sugawara,M. Cobo Dols,M. Perol,C. Mascaux,E. Poddubskaya,

Annals of Oncology (2023): S1665-S1666

引用0浏览0引用

Treatment (tx) patterns and outcomes in resectable early-stage non-small cell lung cancer (NSCLC): A global real-world (rw) study

S. Lin, D. Kahangire,S. Nagar,M-J. Ahn, R. Affi, J. Agulnik,J-Y. Shih, M. J. Hochmair, A. Tufman, D. Debieuvre, J. Chow,M. Jimenez,

JOURNAL OF THORACIC ONCOLOGYno. 4 (2023): S93-S94

引用0浏览0引用

A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC

D. Choi, H. A. Jung, S. Park,J-M. Sun,J. S. Ahn,M-J. Ahn,S-H. Lee

ANNALS OF ONCOLOGY (2023): S1696-S1696

引用0浏览0引用

666P Updated efficacy and safety data of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) solid tumours

S. Lu,F.G.M. De Braud, Y. Fan, X. Hu, Y. Ohe,Y. Yu,M-J. Ahn, P. Cassier,J.J. Lin, L. Paz-Ares, C. Xue, W. Bordogna,

Annals of Oncology (2023): S468-S469

引用0浏览0引用

1549TiP DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE®), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC)

S.M. Gadgeel, J. Al-Mondhiry,M-J. Ahn,S-W. Kim, L. Paz-Ares, H. Prenen, M. Boyer, J.G. Bustamante Alvarez, B. Solomon, S. Huang, M. Minocha, M. Kistler,

Annals of Oncology (2022): S1255-S1255

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn